In vivo hydrodynamic delivery of cDNA encoding IL-2: Rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells

Journal of Immunology

Volumn 175, Issue 2, 2005, Pages 693-699

  Ortaldo, John R ^a   Winkler Pickett, Robin T ^a   Bere Jr , Earl W ^a   Watanabe, Morihiro ^a   Murphy, William J ^b   Wiltrout, Robert H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DNA; INTERLEUKIN 2;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DNA DETERMINATION; EVALUATION; GENE; GENE DELIVERY SYSTEM; HYDRODYNAMICS; IL2 GENE; LEUKOCYTE; LIVER METASTASIS; LUNG METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL;

EID: 23244451649     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.2.693     Document Type: Article

References (32)

1. Blattman, J. N., and P. D. Greenberg. 2004. Cancer immunotherapy: a treatment for the masses. Science 305: 200-205.
2. Phan, G. Q., P. Attia, S. M. Steinberg, D. E. White, and S. A. Rosenberg. 2001. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. 19: 3477-3482.
3. Rosenberg, S. A. 2001. Progress in the development of immunotherapy for the treatment of patients with cancer. J. Intern. Med. 250: 462-475.
4. Yang, J. C., R. M. Sherry, S. M. Steinberg, S. L. Topalian, D. J. Schwartzentruber, P. Hwu, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, D. E. White, et al. 2003. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21: 3127-3132.
5. Wigginton, J. M., E. Grays, L. Geiselhart, J. Subleski, K. L. Komschlies, J. W. Park, T. A. Wiltrout, K. Nagashima, T. C. Back, and R. H. Wiltrout. 2001. IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J. Clin. Invest. 108: 51-62.
6. Wigginton, J. M., and R. H. Wiltrout. 2002. IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. Expert. Opin. Biol. Ther. 2: 513-524.
7. Wigginton, J. M., J. K. Lee, T. A. Wiltrout, W. G. Alvord, J. A. Hixon, J. Subleski, T. C. Back, and R. H. Wiltrout. 2002. Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-γ and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J. Immunol. 169: 4467-4474.
8. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
9. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99: 16168-16173.
10. Dranoff, G. 2003. Coordinated tumor immunity. J. Clin. Invest. 111: 1116-1118.
11. Cooper, M. A., T. A. Fehniger, A. Fuchs, M. Colonna, and M. A. Caligiuri. 2004. NK cell and DC interactions. Trends Immunol. 25: 47-52.
12. Beutler, B. 2004. Innate immunity: an overview. Mol. Immunol. 40: 845-859.
13. Smyth, M. J., Y. Hayakawa, K. Takeda, and H. Yagita. 2002. New aspects of narural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer 2: 850-861.
14. Wiltrout, R. H., R. B. Herberman, S. R. Zhang, M. A. Chirigos, J. R. Ortaldo, K. M. Green, Jr., and J. E. Talmadge. 1985. Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. J. Immunol. 134: 4267-4275.
15. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
16. Crowe, N. Y., M. J. Smyth, and D. I. Godfrey. 2002. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196: 119-127.
17. Smyth, M. J., N. Y. Crowe, Y. Hayakawa, K. Takeda, H. Yagita, and D. I. Godfrey. 2002. NKT cells: conductors of tumor immunity? Curr. Opin. Immunol. 14: 165-171.
18. Terabe, M., S. Matsui, N. Noben-Trauth, H. Chen, C. Watson, D. D. Donaldson, D. P. Carbone, W. E. Paul, and J. A. Berzofsky. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1: 515-520.
19. Terabe, M., and J. A. Berzofsky. 2004. Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol. 16: 157-162.
20. Wiltrout, R. H. 2000. Regulation and antimetastatic functions of liver-associated natural killer cells. Immunol. Rev. 174: 63-76.
21. Kelly, J. M., P. K. Darcy, J. L. Markby, D. I. Godfrey, K. Takeda, H. Yagita, and M. J. Smyth. 2002. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3: 83-90.
22. Donohue, J. H., and S. A. Rosenberg. 1983. The fate of interleukin-2 after in vivo administration. J. Immunol. 130: 2203-2208.
23. Liu, F., Y. Song, and D. Liu. 1999. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6: 1258-1266.
24. He, Y., A. A. Pimenov, J. V. Nayak, J. Plowey, L. D. Falo, Jr., and L. Huang. 2000. Intravenous injection of naked DNA encoding secreted flu ligand dramatically increases the number of dendritic cells and natural killer cells in vivo. Hum. Gene Ther. 11: 547-554.
25. Fogler, W. E., K. Volker, M. Watanabe, J. M. Wigginton, P. Roessler, M. J. Brunda, J. R. Ortaldo, and R. H. Wiltrout. 1998. Recruitment of hepatic NK cells by IL-12 is dependent on IFN-γ and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas. J. Immunol. 161: 6014-6021.
26. Ortaldo, J. R., E. W. Bere, D. Hodge, and H. A. Young. 2001. Activating Ly-49 NK receptors: central role in cytokine and chemokine production. J. Immunol. 166: 4994-4999.
27. Ortaldo, J. R., H. A. Young, R. T. Winkler-Pickett, E. W. Bere, Jr., W. J. Murphy, and R. H. Wiltrout. 2004. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J. Immunol. 172: 943-953.
28. Oberg, L., S. Johansson, J. Michaelsson, P. Hoglund, and K. Karre. 2002. A novel in vivo assay for NK cell mediated elimination of spleen and bone marrow cells. In 19th International Natural Killer Cell Workshop & 7th Annual Meeting of the Society for Natural Immunity, October 6-8. M. Caliguri, ed. San Juan, Puerto Rico, p. 58.
29. Lyons, A. B., and C. R. Parish. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171: 131-137.
30. Talmadge, J. E., R. B. Herberman, M. A. Chirigos, A. E. Maluish, M. A. Schneider, J. S. Adams, H. Philips, G. B. Thurman, L. Varesio, and C. Long. 1985. Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators including recombinant interferons and interleukin 2. J. Immunol. 135: 2483-2491.
31. Herberman, R. B. 2002. Cancer immunotherapy with natural killer cells. Semin. Oncol. 29: 27-30.
32. Wu, J., and L. L. Lanier. 2003. Natural killer cells and cancer. Adv. Cancer Res. 90: 127-156.